PharmaResearch said its annual sales topped 500 billion won for the first time in 2025, driven by growth in its medical device and cosmetics businesses.
In a regulatory filing on Tuesday, the company said 2025 revenue rose 53% from a year earlier to 535.7 billion won on a consolidated basis. Operating profit increased 70% to 214.2 billion won.
The company said it posted broad-based growth across all business segments, with medical devices and cosmetics leading results. “An increase in domestic demand tied to an inflow of foreign tourists and rising exports centered on medical devices and cosmetics worked together,” the company said.
Medical device sales grew 62% from a year earlier, and cosmetics sales surged 69%, led by major overseas markets including the United States and Japan, the company said.
PharmaResearch said it plans to accelerate its mid- to long-term global expansion. It will begin European sales of “Rejuran,” which drew attention at the world’s largest aesthetic plastic surgery conference, IMCAS, held last month in Paris. The company also plans to enter the Middle East and South America to diversify markets. It said it will start with Chile, Peru, Argentina and Mexico, and will seek approval in Brazil, the region’s largest market, to expand further in Latin America.
The company said it will continue investing in research and development to diversify its portfolio, including expanding its product lineup to cancer treatments and beginning clinical trials aimed at securing approval in Japan, in addition to its pharmaceuticals, medical devices, cosmetics and health functional foods.
A PharmaResearch official said 2025 was “a year in which we laid the foundation for a global leap through meaningful growth,” adding that the company maintained steady growth even before results from Europe were fully reflected in earnings. The official said the company plans to invest in facilities to stabilize its global supply chain and strengthen R&D to speed entry into countries where it has not yet received approvals, while reinforcing leadership in the skin booster market.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.